Bio-Techne Corp (TECH) Q3 2026 Earnings Call Transcript

Why It Matters

The results show Bio‑Techne’s ability to sustain profitability despite market headwinds, and underscore the strategic shift toward high‑growth verticals that could drive future revenue acceleration.

Key Takeaways

• Revenue flat at $295.9M, FX offset by sale headwinds
• Adjusted operating margin rose to 31.1%, +100 bps
• Cell therapy revenue down >30% due to FDA timing
• Spatial biology bookings up ~40%, accelerating platform adoption
• Four growth verticals now 47% of revenue, up from 32%

Pulse Analysis

Bio‑Techne’s Q3 performance illustrates how a diversified life‑science tools portfolio can buffer macro‑level volatility. While overall revenue remained flat, the company leveraged cost‑discipline and favorable foreign‑exchange effects to lift adjusted operating margin above 30%. This margin expansion, coupled with modest EPS growth, signals that the firm’s pricing power and operational efficiency remain intact even as certain segments, such as cell‑therapy reagents, experience temporary demand dips tied to regulatory timing. Investors should note that the decline in GMP reagent sales is largely a short‑term anomaly, with underlying demand rebounding when the two large customers resume regular ordering cycles.

The real growth story lies in Bio‑Techne’s strategic verticals—cell therapy, proteomic analytical instrumentation, spatial biology, and precision diagnostics—which now account for nearly half of total revenue. Spatial biology, in particular, is gaining traction; the Comet platform’s bookings surged close to 40%, reflecting broader adoption of multi‑omic, high‑throughput tissue analysis in both academic and commercial labs. This momentum is reinforced by product innovations such as ultra‑sensitive Ella assays and the next‑generation LEO western blot system, which expand the company’s addressable market and deepen customer lock‑in. As the organoid market matures, Bio‑Techne’s $50 million run‑rate and new synthetic hydrogel offering position it to capture a share of the projected $1.4 billion global market.

Geographically, the firm is benefitting from robust growth in China and the broader APAC region, where demand for advanced therapy reagents and analytical tools is rising sharply. Meanwhile, the U.S. academic segment faces modest declines, offset by stable European sales. Looking ahead, Bio‑Techne’s guidance for margin expansion and mid‑single‑digit organic growth suggests that the temporary headwinds are receding. The pending full acquisition of Wilson Wolf’s G‑Rex bioreactors further integrates cell‑therapy manufacturing capabilities, creating cross‑selling opportunities that could accelerate revenue diversification and sustain long‑term earnings momentum.